Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FIRST QUARTER

2009

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	1Q ‘09		1Q ‘08
MERCK / SCHERING-PLOUGH	$	290.9	$	392.8
ASTRAZENECA LP		168.3		131.1
Other (1)		126.6		128.2
TOTAL	$	585.8	$	652.1
(1)      Primarily reflects results for Merial Limited, Sanofi Pasteur MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a "NET" basis.

Merial	1Q ‘09		1Q ‘08
FRONTLINE, other fipronil	$	306.9	$	341.6
BIOLOGICALS		171.9		174.4
IVOMEC, HEARTGARD, other avermectins		134.7		146.1
Other Animal Health		70.6		71.5
TOTAL MERIAL SALES	$	684.1	$	733.6
Sanofi Pasteur-MSD	1Q ‘09		1Q ‘08
GARDASIL	$	164.1	$	239.8
OTHER VIRAL VACCINES		25.4		22.7
HEPATITIS VACCINES		13.4		18.0
ROTATEQ		8.7		6.0
Other Vaccines		131.7		124.9
TOTAL SANOFI PASTEUR-MSD SALES	$	343.3	$	411.4
Merck / Schering-Plough Collaboration	1Q ‘09		1Q ‘08
VYTORIN	$	466.0	$	651.2
ZETIA		479.3		581.7
TOTAL MERCK / SCHERING-PLOUGH SALES	$	945.3	$	1,232.9

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	1Q ‘09			1Q ‘08
INTEREST INCOME	$	(96.3	)	$	(169.5	)
INTEREST EXPENSE		60.7			72.6
EXCHANGE LOSSES		16.5			12.6
Other, net (1)		(48.1	)		(2,124.9	)
TOTAL	$	(67.2	)	$	(2,209.2	)
(1)      Other, net in the first quarter of 2008 primarily reflects a $2.2 billion gain on distribution from AstraZeneca LP.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FIRST QUARTER

2009

NET PRODUCT SALES DETAIL (millions of dollars)

	1Q ‘09 vs. 1Q ‘08
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	-1	%	839	2	%	304	-2	%	535
JANUVIA	51	%	411	38	%	313	*		98
JANUMET	*		128	83	%	100	*		28
SINGULAIR	-4	%	1,057	-4	%	682	-4	%	375
Vaccines:
GARDASIL	-33	%	262	-39	%	179	-14	%	83
ROTATEQ	-29	%	134	-31	%	124	-7	%	10
ZOSTAVAX	2	%	75	2	%	75	N/A		—
OTHER VIRAL VACCINES (1)	12	%	252	16	%	235	-28	%	17
HEPATITIS VACCINES (2)	2	%	35	16	%	29	-36	%	6
OTHER VACCINES (3)	-23	%	56	2	%	30	-41	%	26
Other Reported Products:
ARCOXIA	-13	%	81	N/A		—	-13	%	81
CANCIDAS	-7	%	139	-37	%	19	1	%	120
COSOPT / TRUSOPT	-40	%	121	-83	%	14	-11	%	107
CRIXIVAN / STOCRIN	-35	%	49	-23	%	3	-35	%	46
EMEND	16	%	69	9	%	44	30	%	25
FOSAMAX	-44	%	261	-80	%	41	-18	%	220
INVANZ	11	%	62	17	%	33	5	%	29
ISENTRESS	*		148	*		75	*		73
MAXALT	10	%	133	18	%	92	-5	%	41
PRIMAXIN	-19	%	165	-41	%	30	-11	%	134
PROPECIA	-2	%	103	-3	%	36	-2	%	67
PROSCAR	-15	%	72	-54	%	1	-14	%	71
TIMOPTIC / TIMOPTIC XE	-5	%	28	-58	%	1	-1	%	27
VASOTEC / VASERETIC	-19	%	77	N/A		—	-19	%	77
ZOCOR	-23	%	137	-70	%	8	-15	%	129
ZOLINZA	15	%	5	16	%	4	-6	%	—

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ - Includes Recombivax and Vaqta

⁽³⁾ - Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	1Q ‘09		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	5,385	-8	%	-6	1	-3
U.S. ($ MM)		2,957	-10	%	-15	4	N/A
Foreign ($ MM)		2,428	-4	%	6	-2	-8